Skip to content

Telehealth in an Ambulatory Oncology Phase I Clinical Trial Unit

Telehealth as a Nursing Strategy for Monitoring Patients in an Ambulatory Oncology Phase I Clinical Trial Unit

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07069868
Enrollment
21
Registered
2025-07-17
Start date
2021-08-12
Completion date
2022-03-24
Last updated
2025-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Neoplasm

Keywords

telemedicine, nursing, Phase 1 oncology clinical trial

Brief summary

The study aimed to evaluate the feasibility, acceptability, satisfaction and effectiveness of telehealth on early identification and mitigation of adverse events during cycle one of a Phase 1 oncology clinical trial.

Detailed description

Oncology patients in Phase 1 clinical trials receive study medications administered for the first time in humans. Participants need to be monitored closely for adverse events which can be serious and have critical implications. A single group repeated measures design was used to evaluate the effect of telehealth on patient outcomes and patient experience for up to four telehealth sessions and nursing staff perceptions of telehealth. Enrollment was limited to 21 participants, in order to limit the number of patients for a pilot study. Telehealth sessions began within seven days after the initial treatment and occurred weekly during cycle one of the participant's Phase 1 protocol. Side effects assessed by nursing included mucositis, nausea, vomiting, constipation, diarrhea, dyspnea, cough, rash, pain and fever. Patients were also given the opportunity to address other symptoms. Original research was required to establish validity of telehealth for managing adverse events, dose limiting toxicities of study medications, and enhancing safe clinical care with potentially meeting unmet patient needs when beginning an oncology Phase 1 clinical trial. Data Collection tools included: 1. Data collection Table which includes variables, sources of data and timeframes 2. Charlson Comorbidity Index (CCI) 3. Patient Reported Outcomes-Common Terminology for Adverse Events (PRO-CTCAE) 4. Adverse Event for Mucositis 5. Adverse Event for Nausea 6. Adverse Event for Vomiting 7. Adverse Event for Constipation 8. Adverse Event for Diarrhea 9. Adverse Event for Dyspnea 10. Adverse Event for Cough 11. Adverse Event for Acneiform Rash 12. Adverse Event for Maculo-Papular Rash 13. Adverse Event for Pain 14. Adverse Event for Fever 15. Nursing Perception of Telehealth Survey 16. Feasibility of Intervention Measure (FIM). Nursing Perspective on the Feasibility of Utilizing Telehealth Technology Survey 17. Nursing Experience with Telehealth and Patients' Adverse Events Survey 18. Patient Feasibility Survey 19. Acceptability of Intervention Measure (AIM). Patient Experience with Accessibility Related to Telehealth Sessions 20. Patient Experience with Telehealth Survey

Interventions

OTHERTelehealth

During cycle one, participants will be asked about fevers, mucositis, nausea, vomiting, constipation, diarrhea, dyspnea, cough, rash, pain and fever. Symptoms will be graded according to Common Terminology Criteria for Adverse Events. A new adverse event of grade one or higher will be reported to a provider. An adverse event grade two or higher above baseline and/or experiencing cancer related symptoms above baseline, the findings will be reported to a Provider.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

A quasi-experimental study of weekly telehealth visits was conducted using a single-group repeated measures design for adults with cancer enrolled in cycle one Phase 1 clinical trials.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Cancer diagnosis * Consented and registered to a Phase I oncology clinical trial * Cycle one patient * 18 years of age or older * Willing to participate in weekly telehealth sessions during cycle one * Patient Gateway account * Zoom video application downloaded and installed * A reliable internet connection * A device with the following requirements PC/Mac with: 1. Chrome or Firefox as an internet browser 2. Webcam 3. Microphone 4. Speakers or Headphones iPhone/iPad/Android Device with: 1. The Partners Patient Gateway Application 2. Front facing camera

Exclusion criteria

* Adults who are unable to consent * Individuals younger than 18 years old * Pregnant women * Prisoners

Design outcomes

Primary

MeasureTime frameDescription
The study will be feasible as measured by the Feasibility of Intervention at study completion.From enrollment to the end of cycle one which can be up to 28 days.Measures were scored via a Linkert scale ranging from 1 to 5. The higher the score indicates feasibility. 1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree and 5 = completely agree. Feasibility was measured by patients and nurses to see if telehealth would be feasible if implemented in a Phase 1 oncology clinical trial unit.

Secondary

MeasureTime frameDescription
The study will be acceptable as measured by the Acceptability of Intervention Measure at study completion.From enrollment to the end of cycle one which can be up to 28 days.Measures were scored via a Linkert scale ranging from 1 to 5. The higher the score indicates acceptability. 1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree and 5 = completely agree. Acceptability was measured by patients and nurses to see if telehealth would be acceptable for patients and staff in a Phase 1 oncology clinical trial unit.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026